Cargando…

Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target

Pancreatic-related disorders such as pancreatitis, pancreatic cancer, and type 1 diabetes mellitus (T1DM) impose a substantial challenge to human health and wellbeing. Even though our understanding of the initiation and progression of pancreatic diseases has broadened over time, no effective therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tao, Gao, Guangqi, Sakandar, Hafiz Arbab, Kwok, Lai-Yu, Sun, Zhihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885515/
https://www.ncbi.nlm.nih.gov/pubmed/35242797
http://dx.doi.org/10.3389/fnut.2022.814269
_version_ 1784660439667310592
author Zhang, Tao
Gao, Guangqi
Sakandar, Hafiz Arbab
Kwok, Lai-Yu
Sun, Zhihong
author_facet Zhang, Tao
Gao, Guangqi
Sakandar, Hafiz Arbab
Kwok, Lai-Yu
Sun, Zhihong
author_sort Zhang, Tao
collection PubMed
description Pancreatic-related disorders such as pancreatitis, pancreatic cancer, and type 1 diabetes mellitus (T1DM) impose a substantial challenge to human health and wellbeing. Even though our understanding of the initiation and progression of pancreatic diseases has broadened over time, no effective therapeutics is yet available for these disorders. Mounting evidence suggests that gut dysbiosis is closely related to human health and disease, and pancreatic diseases are no exception. Now much effort is under way to explore the correlation and eventually potential causation between the gut microbiome and the course of pancreatic diseases, as well as to develop novel preventive and/or therapeutic strategies of targeted microbiome modulation by probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) for these multifactorial disorders. Attempts to dissect the intestinal microbial landscape and its metabolic profile might enable deep insight into a holistic picture of these complex conditions. This article aims to review the subtle yet intimate nexus loop between the gut microbiome and pancreatic diseases, with a particular focus on current evidence supporting the feasibility of preventing and controlling pancreatic diseases via microbiome-based therapeutics and therapies.
format Online
Article
Text
id pubmed-8885515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88855152022-03-02 Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target Zhang, Tao Gao, Guangqi Sakandar, Hafiz Arbab Kwok, Lai-Yu Sun, Zhihong Front Nutr Nutrition Pancreatic-related disorders such as pancreatitis, pancreatic cancer, and type 1 diabetes mellitus (T1DM) impose a substantial challenge to human health and wellbeing. Even though our understanding of the initiation and progression of pancreatic diseases has broadened over time, no effective therapeutics is yet available for these disorders. Mounting evidence suggests that gut dysbiosis is closely related to human health and disease, and pancreatic diseases are no exception. Now much effort is under way to explore the correlation and eventually potential causation between the gut microbiome and the course of pancreatic diseases, as well as to develop novel preventive and/or therapeutic strategies of targeted microbiome modulation by probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) for these multifactorial disorders. Attempts to dissect the intestinal microbial landscape and its metabolic profile might enable deep insight into a holistic picture of these complex conditions. This article aims to review the subtle yet intimate nexus loop between the gut microbiome and pancreatic diseases, with a particular focus on current evidence supporting the feasibility of preventing and controlling pancreatic diseases via microbiome-based therapeutics and therapies. Frontiers Media S.A. 2022-02-15 /pmc/articles/PMC8885515/ /pubmed/35242797 http://dx.doi.org/10.3389/fnut.2022.814269 Text en Copyright © 2022 Zhang, Gao, Sakandar, Kwok and Sun. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Zhang, Tao
Gao, Guangqi
Sakandar, Hafiz Arbab
Kwok, Lai-Yu
Sun, Zhihong
Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target
title Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target
title_full Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target
title_fullStr Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target
title_full_unstemmed Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target
title_short Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target
title_sort gut dysbiosis in pancreatic diseases: a causative factor and a novel therapeutic target
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885515/
https://www.ncbi.nlm.nih.gov/pubmed/35242797
http://dx.doi.org/10.3389/fnut.2022.814269
work_keys_str_mv AT zhangtao gutdysbiosisinpancreaticdiseasesacausativefactorandanoveltherapeutictarget
AT gaoguangqi gutdysbiosisinpancreaticdiseasesacausativefactorandanoveltherapeutictarget
AT sakandarhafizarbab gutdysbiosisinpancreaticdiseasesacausativefactorandanoveltherapeutictarget
AT kwoklaiyu gutdysbiosisinpancreaticdiseasesacausativefactorandanoveltherapeutictarget
AT sunzhihong gutdysbiosisinpancreaticdiseasesacausativefactorandanoveltherapeutictarget